BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 26261061)

  • 1. AGXT and ERCC2 polymorphisms are associated with clinical outcome in metastatic colorectal cancer patients treated with 5-FU/oxaliplatin.
    Kjersem JB; Thomsen M; Guren T; Hamfjord J; Carlsson G; Gustavsson B; Ikdahl T; Indrebø G; Pfeiffer P; Lingjærde O; Tveit KM; Wettergren Y; Kure EH
    Pharmacogenomics J; 2016 Jun; 16(3):272-9. PubMed ID: 26261061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of DNA repair gene variants with colorectal cancer: risk, toxicity, and survival.
    Salimzadeh H; Lindskog EB; Gustavsson B; Wettergren Y; Ljungman D
    BMC Cancer; 2020 May; 20(1):409. PubMed ID: 32397974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05.
    Boige V; Mendiboure J; Pignon JP; Loriot MA; Castaing M; Barrois M; Malka D; Trégouët DA; Bouché O; Le Corre D; Miran I; Mulot C; Ducreux M; Beaune P; Laurent-Puig P
    J Clin Oncol; 2010 May; 28(15):2556-64. PubMed ID: 20385995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimen.
    Cecchin E; D'Andrea M; Lonardi S; Zanusso C; Pella N; Errante D; De Mattia E; Polesel J; Innocenti F; Toffoli G
    Pharmacogenomics J; 2013 Oct; 13(5):403-9. PubMed ID: 22868256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer.
    Stoehlmacher J; Park DJ; Zhang W; Yang D; Groshen S; Zahedy S; Lenz HJ
    Br J Cancer; 2004 Jul; 91(2):344-54. PubMed ID: 15213713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single nucleotide polymorphisms in nucleotide excision repair genes XPA, XPD, XPG and ERCC1 in advanced colorectal cancer patients treated with first-line oxaliplatin/fluoropyrimidine.
    Monzo M; Moreno I; Navarro A; Ibeas R; Artells R; Gel B; Martinez F; Moreno J; Hernandez R; Navarro-Vigo M
    Oncology; 2007; 72(5-6):364-70. PubMed ID: 18204222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis.
    Zarate R; Rodríguez J; Bandres E; Patiño-Garcia A; Ponz-Sarvise M; Viudez A; Ramirez N; Bitarte N; Chopitea A; Gacía-Foncillas J
    Br J Cancer; 2010 Mar; 102(6):987-94. PubMed ID: 20216541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenetics of oxaliplatin as adjuvant treatment in colon carcinoma: are single nucleotide polymorphisms in GSTP1, ERCC1, and ERCC2 good predictive markers?
    Fariña Sarasqueta A; van Lijnschoten G; Lemmens VE; Rutten HJ; van den Brule AJ
    Mol Diagn Ther; 2011 Oct; 15(5):277-83. PubMed ID: 21958378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ERCC1 and ERCC2 as predictive biomarkers to oxaliplatin-based chemotherapy in colorectal cancer patients from Egypt.
    Kassem AB; Salem SE; Abdelrahim ME; Said AS; Salahuddin A; Hussein MM; Bahnassy AA
    Exp Mol Pathol; 2017 Feb; 102(1):78-85. PubMed ID: 28088319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influences of ERCC1, ERCC2, XRCC1, GSTP1, GSTT1, and MTHFR polymorphisms on clinical outcomes in gastric cancer patients treated with EOF chemotherapy.
    Liu R; Zhao X; Liu X; Chen Z; Qiu L; Geng R; Guo W; He G; Yin J; Li J; Zhu X
    Tumour Biol; 2016 Feb; 37(2):1753-62. PubMed ID: 26314858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The combination of ERCC1 and XRCC1 gene polymorphisms better predicts clinical outcome to oxaliplatin-based chemotherapy in metastatic colorectal cancer.
    Liang J; Jiang T; Yao RY; Liu ZM; Lv HY; Qi WW
    Cancer Chemother Pharmacol; 2010 Aug; 66(3):493-500. PubMed ID: 19960344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic variability of DNA repair mechanisms influences chemotherapy outcome of gastric cancer.
    Yu H; Wu X; Zhang Y; Jin Z; Li G; Zhao H
    Int J Clin Exp Pathol; 2015; 8(4):4106-12. PubMed ID: 26097599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GSTP1, ERCC1 and ERCC2 polymorphisms, expression and clinical outcome of oxaliplatin-based adjuvant chemotherapy in colorectal cancer in Chinese population.
    Li HY; Ge X; Huang GM; Li KY; Zhao JQ; Yu XM; Bi WS; Wang YL
    Asian Pac J Cancer Prev; 2012; 13(7):3465-9. PubMed ID: 22994779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlations between microsatellite instability, ERCC1/XRCC1 polymorphism and clinical characteristics, and FOLFOX adjuvant chemotherapy effect of colorectal cancer patients.
    Zhang L; Zhao J; Yu B; Song X; Sun G; Han L; Wang L; Dong S
    Cancer Genet; 2017 Dec; 218-219():51-57. PubMed ID: 29153096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer.
    Chua W; Goldstein D; Lee CK; Dhillon H; Michael M; Mitchell P; Clarke SJ; Iacopetta B
    Br J Cancer; 2009 Sep; 101(6):998-1004. PubMed ID: 19672255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II trial of FOLFOX6 and cetuximab in the first-line treatment of patients with metastatic colorectal cancer.
    Boccia RV; Cosgriff TM; Headley DL; Badarinath S; Dakhil SR
    Clin Colorectal Cancer; 2010 Apr; 9(2):102-7. PubMed ID: 20378504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Relationship between single nucleotide polymorphism in repair gene XPD751 and prognosis in colorectal carcinoma patients].
    Chen YM; Wu XL; Zhang LW; Xu X; Liu JW
    Zhonghua Zhong Liu Za Zhi; 2012 Jul; 34(7):501-5. PubMed ID: 22967467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential toxicity biomarkers for irinotecan- and oxaliplatin-containing chemotherapy in colorectal cancer.
    Cortejoso L; García MI; García-Alfonso P; González-Haba E; Escolar F; Sanjurjo M; López-Fernández LA
    Cancer Chemother Pharmacol; 2013 Jun; 71(6):1463-72. PubMed ID: 23543295
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of a comprehensive panel of biomarkers to predict response to a fluorouracil-oxaliplatin regimen in patients with metastatic colorectal cancer.
    Lamas MJ; Duran G; Balboa E; Bernardez B; Touris M; Vidal Y; Gallardo E; Lopez R; Carracedo A; Barros F
    Pharmacogenomics; 2011 Mar; 12(3):433-42. PubMed ID: 21449681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive value of ERCC1, ERCC2, and XRCC1 overexpression for stage III colorectal cancer patients receiving FOLFOX-4 adjuvant chemotherapy.
    Huang MY; Tsai HL; Lin CH; Huang CW; Ma CJ; Huang CM; Chai CY; Wang JY
    J Surg Oncol; 2013 Dec; 108(7):457-64. PubMed ID: 23996617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.